| 中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
|---|---|---|---|---|
| 杯[4]芳烃 | 25,26,27,28-tetrakis(hydroxy)calix[4]arene | 74568-07-3 | C28H24O4 | 424.496 |
| 中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
|---|---|---|---|---|
| —— | 12,32,72-tris(decyloxy)-52-((10-hydroxydecyl)oxy)-1,3,5,7(1,3)-tetrabenzenacyclooctaphane-15,55-dicarbonitrile | 666849-80-5 | C70H102N2O5 | 1051.59 |
| —— | 10-((15,55-dibromo-32,52,72-tris(decyloxy)-1,3,5,7(1,3)-tetrabenzenacyclooctaphane-12-yl)oxy)decan-1-ol | 666849-79-2 | C68H102Br2O5 | 1159.36 |
The lack of targeting, severe toxicity on normal tissues have become an intractable limitation of doxorubicin (DOX)-based chemotherapy. A biotin-modified calix[4]arene based therapeutic agent BPCA4 has been designed for the delivery of DOX to alleviate the adverse side effects.